Retroviral insertional mutagenesis screens (Lund et al. 2002; Mikkers et al. 2002; Suzuki et al. 2002) and transposon-based screens (Collier et al. 2005; Dupuy et al. 2005) have been used as powerful tools for cancer gene discovery in hematopoietic and solid tumors. These screens have identified numerous previously uncharacterized genes that drive tumor initiation and progression. Using RNAi-based screening, it is possible to examine hypomorphic phenotypes in mammalian cells (Berns et al. 2004; Paddison et al. 2004; Ngo et al. 2006; Schlabach et al. 2008; Silva et al. 2008) . Recently, pool-based shRNA screening approaches have been adapted to in vivo applications in transplantable tumors. shRNA pools were used to screen for tumor suppressors in mouse models of liver cancer (Zender et al. 2008 ), B-cell lymphoma (Bric et al. 2009 ), and skin carcinomas (Beronja et al. 2013) . Here, we adapted a poolbased shRNA screening strategy for use in a transplantable mouse model of B-cell acute lymphoblastic leukemia (ALL) (Williams et al. 2006) . Specifically, we introduced libraries of retrovirally expressed shRNAs into leukemia cells and transplanted transduced cells into recipient animals to screen for genes that impact leukemia cell growth. In this ALL model, the transplantation of murine p19
ArfÀ/À pre-B cells that express the p185 BCR-ABL fusion protein (Arf-null, p185 + ) into immune-competent syngeneic mice produces an aggressive, disseminated polyclonal B-cell leukemia within ;2 wk (Williams et al. 2006 (Williams et al. , 2007 . Importantly, since leukemias are established within wildtype syngeneic recipient animals, tumor cell growth occurs in the context of a normal microenvironment and in the presence of a functional immune system.
Results and Discussion
To determine whether large, unbiased shRNA sets could be introduced into disseminated leukemias in vivo, we made use of a genome-scale shRNA library composed of five pools of shRNAs containing ;10,000 hairpins each. Leukemia cells were transduced with single pools of 10,000 shRNAs, and infected cells were injected into recipient mice or, in parallel, placed in culture. Growth in both contexts allowed us to compare shRNAs that impact leukemia cell proliferation in vitro and in vivo. In control experiments, we observed rapid homing of leukemia cells to the bone marrow and spleen following transplantation (Supplemental Fig. 1A,B) , indicating that leukemia cell proliferation occurs within these physiological environments in vivo. Once overt disease developed, leukemia cells were harvested from the blood of the recipient animals and from cultured samples, and shRNA representation was deconvoluted via high-throughput sequencing (Fig. 1A) . Here, we could detect, on average, between 7000 and 8000 unique hairpins in the peripheral leukemia burden derived from individual mice ( Fig. 1B; Supplemental Fig. 2A ). To assess the upper limit of the number of hairpins that can be detected in the leukemia burden from individual mice, we combined all five pools of shRNAs and introduced this set of 50,000 hairpins into tumor cells prior to transplantation. Here, we could identify as many as 30,000 unique shRNAs in tumors from individual animals at the onset of terminal disease (Supplemental Fig. 2B,C) . Thus, given the high engraftment efficiency in this model of B-ALL, we can represent genome-scale shRNA libraries in vivo.
As an initial survey of the data set produced from the 50,000 shRNA pool, the shRNA representation from cultured cells or mice was subjected to hierarchical clustering based on the enrichment and depletion of shRNAs within each sample. Here, the in vivo and in vitro samples clustered as distinct groups (Fig. 1D) the phenotypes conferred by the same hairpins in vivo ( Fig. 1C,E; Supplemental Fig. 3A) , with limited mutual information provided when comparing rank-order lists of enriched and depleted shRNAs in cell culture and mice. For validation studies, we focused on shRNAs that depleted specifically in the in vivo setting, as these genes represent a putative new class of leukemia drug targets. To prioritize shRNAs for validation studies, hairpins that depleted an average of fourfold in vivo and did not deplete >25% in vitro were considered candidates for validation. Using these criteria, we identified ;1700 scoring hairpins that targeted annotated genes, predicted genes, and predicted proteins (Supplemental Tables 1, 2) .
Relative to the in vitro data set, the in vivo data set showed high mouse-to-mouse variability, ( Fig. 1D ; Supplemental Fig. 3 ), suggesting that transplantation and engraftment as well as the complexity of the in vivo microenvironment can substantially influence the measured effect of a relatively neutral shRNA. However, further inspection of this variation showed that a subset of shRNAs had lower coefficients of variation (CVs) between mice. When we examined the CVs between mice for our putative ''scoring shRNAs,'' the average CVs for these hairpins was significantly lower than the average CV in vivo (Supplemental Fig. 3B-D) , and the CVs of candidate depletion hits were of a size comparable with those produced by shRNAs that exerted consistent biological effects in previous smallscale screens. In contrast, randomly selected shRNAs, validated for neutrality, showed greater variability and reduced fold change in our data set (Supplemental Fig. 3B) . Thus, the set of low CV shRNAs from our screen is enriched for validating shRNAs.
Functional categorization of the genes targeted by the 1700 scoring shRNAs (Huang et al. 2009a,b) based on structural features of proteins encoded by target genes revealed that these genes were enriched for a number of common domains ( Fig. 2A ; Supplemental Table 2B ). These domains included C 2 H 2 -type zinc finger protein domains, which primarily regulate gene expression (Iuchi 2001) ; Kelch and BTB/POZ domains, which are involved in protein-protein interactions and regulate diverse cellular processes (Collins et al. 2001) ; and plant homeodomain (PHD) fingers, which recognize specific histone modifications and are part of multimeric complexes that can activate or repress gene transcription (Musselman and Kutateladze 2011; Sanchez and Zhou 2011) . To assess the impact of a given hairpin on tumor cell growth, leukemia cells were partially transduced with single shRNAs coexpressing GFP and injected into recipient mice or maintained in culture. After a period of in vitro or in vivo proliferation, the percentage of GFP-positive (shRNAexpressing) cells was assayed by flow cytometry (Supplemental Fig. 4A ). In total, out of the 18 shRNAs tested targeting genes containing Kelch and C 2 H 2 zinc finger domains, nine depleted as single constructs. Importantly, eight of these nine shRNAs differentially impacted leukemia cell growth in vivo and in vitro (Fig. 2B,C) . The deleterious effect of shRNA-mediated gene suppression in vivo was confirmed with second hairpins for these targets (Supplemental Fig. 4B ). While these hairpins were neutral or, in some instances, provided a growth advantage in the in vitro context, they depleted during tumor expansion in mice. Thus, by performing screens in mice, we identified a number of genes that represent putative in vivo ''context-specific'' cancer dependencies that would not be identified in cell culture-based screens.
To further prioritize shRNAs for validation, we generated transcriptional data from leukemia cells grown in vitro and in vivo (Supplemental Fig. 5A ). Specifically, we compared the genes that were transcriptionally upregulated in vivo with those that were targeted by hairpins that depleted specifically in vivo. Notably, only a small proportion of genes overlapped between the transcriptional and screening data sets (Supplemental Fig. 5B ,C; Supplemental Table 3 ), a phenomenon that has also been observed when comparing functional and transcriptional data in other settings (Yeger-Lotem et al. 2009 ). To more extensively probe this overlapping gene set, we built a high-coverage validation library that contained six independent shRNAs directed against each of the 133 genes in this set (Fig. 2D ). Only genes that had multiple independent shRNAs deplete specifically in vivo, but not in cell culture, in this secondary screen (Supplemental Table  4 ) were considered candidates for follow-up studies. By this criteria, this secondary screen validated 77 of the starting 133 genes (58%) as context-specific positive regulators of tumor growth, and a subset of these was further validated as single shRNA constructs ( Fig. 2E; Supplemental Fig.  5C ). Consistent with our previous observations, shRNAs targeting these 77 genes produced lower CVs than the nonscoring shRNAs (Supplemental Fig. 3D) .
Two of the shRNAs that depleted specifically in the in vivo setting targeted Lmo2 and Runx1 (Fig. 2F) , genes with established roles in hematopoietic malignancies. LMO2 translocations, resulting in overexpression of the fulllength Lmo2 protein, are found in T-cell malignancies and have been suggested, at least in part, to promote tumorigenesis by blocking T-cell development McCormack et al. 2010) . Thus far, LMO2 does not have a well-established role in the development of B-cell malignancies. Whereas inactivating mutations and translocations resulting in the truncation of RUNX1 are observed in myeloid and T-cell malignancies (Cameron and Neil 2004) , full-length RUNX1 is expressed on translocated alleles in B-cell malignancies (Golub et al. 1995; Romana et al. 1995) . Here, both Runx1 and Lmo2 are transcriptionally up-regulated in the in vivo setting (Supplemental Fig. 6A ), and multiple hairpins targeting these genes confer a growth disadvantage specifically in vivo ( Fig. 2F; Supplemental Fig. 6B,C) . These data indicate that, in vivo, BCR-ABL-driven B-cell leukemia progression is dependent on Runx and Lmo2 function.
As a final means of examining our shRNA screening data using existing biological data sets, we compared genes targeted by shRNAs that depleted in vivo with genes contained within amplicons found in human ALL patients (Kuiper et al. 2007; Mullighan et al. 2008; Zhang et al. 2012) . We mapped the genomic locations of the human orthologs of genes targeted by scoring shRNAs and looked for genes that fell within the amplified regions. In validation experiments, a number of shRNAs targeting genes contained within ALL amplicons conferred minor negative growth effects specifically in vivo (Fig. 3A) . In contrast, hairpins targeting the PHD finger protein Phf6, located in the XQ26 amplicon, yielded a more pronounced negative growth effect in validation Phf6 is a lineage-specific regulator of leukemia experiments, and selection against Phf6 suppression was observed in B-ALLs proliferating in vivo but not in vitro (Fig. 3B) . Inactivating mutations in PHF6 are the cause of B€ orjeson-Forssman-Lehman syndrome (BFLS), an Xlinked intellectual disability (XLID) disorder (Lower et al. 2002) . Recently, inactivating PHF6 mutations have been identified in ;25%-30% of human T-cell ALLs (Van Vlierberghe et al. 2010; Zhang et al. 2012 ) and in 2%-3% of acute myeloid leukemias (AMLs) (Supplemental Table 5 ; Van Vlierberghe et al. 2011; Patel et al. 2012; Yoo et al. 2012) . While the mutational status of PHF6 has been examined in >100 human B-lineage ALLs (Van Vlierberghe et al. 2010; Zhang et al. 2012) , no PHF6 mutations have been observed in these tumors (Supplemental Table 5 ), suggesting that inactivating mutations do not promote malignant growth in B-ALL. Strikingly, our data indicate that suppression of Phf6 actually impairs disease progression in B-cell ALLs, specifically in the in vivo setting.
The strength of the phenotype conferred by Phf6 suppression correlated with the degree of hairpin-mediated gene knockdown (Supplemental Fig. 7A ), and expression of a nontargetable Phf6 cDNA suppressed the deleterious effect of a Phf6 shRNA on tumor cell growth (Fig. 3C ). Phf6 suppression negatively impacted B-cell tumor growth in all hematopoietic organs tested (Fig. 3D) , and we observed a reduction in peripheral leukemia burden in sorted, transplanted populations of leukemia cells transduced with an shRNA targeting Phf6 relative to a vector control (Fig.  3E ). This effect could be due to either impaired tumor growth or impaired tumor engraftment. To differentiate between these possibilities, we monitored the effect of Phf6 suppression on leukemia growth in vivo at sequential time points during disease progression and found that the proportion of cells suppressing Phf6 decreased progressively during disease progression (Fig. 3F) . Thus, Phf6 suppression impairs leukemia cell growth or survival rather than impairing engraftment following transplantation.
To determine whether Phf6 is required for the growth of B-cell malignancies driven by other oncogenic lesions, we also tested the effect of Phf6 suppression in B-cell lymphomas derived from Em-Myc mice, which are driven by expression of high levels of c-Myc. Here, suppression of Phf6 was also specifically selected against in the in vivo context in transplanted B-cell lymphomas (Fig. 3G) . Additionally, Phf6 suppression had no effect on nontransformed pre-B cells (Supplemental Fig. 7B ). Together, these data suggest that Phf6 may be required for the maintenance of the transformed B-cell malignant state in B-cell diseases driven by distinct initiating oncogenes. We then tested the effect of Phf6 suppression in transplantable mouse models of acute leukemia and lymphoma and found that hairpinmediated suppression of Phf6 had a neutral effect in T-cell lymphomas but promoted significant myeloid tumor cell (AML) growth in vivo (Fig. 3H,I ). Together, these findings suggest differential requirements for Phf6 gene function in B-cell, T-cell, and myeloid tumors.
We next tested the effect of cDNA-mediated Phf6 overexpression in vivo in these transplantable murine tumor models and found that Phf6 overexpression was potently selected against in T-cell lymphomas in vivo (Fig. 3I) , whereas it was neutral in B-cell ALLs in vivo (Supplemental Fig. 7C ). These results support a lineage-specific role for Phf6 in hematopoietic malignancies such that overexpression of Phf6 impairs tumor cell growth in T-cell malignancies, and suppression of Phf6 hinders disease progression in B-cell malignancies. These findings are consistent with human mutational data, where inactivating mutations in PHF6 are observed in T-cell and myeloid malignancies but have never been identified in B-cell malignancies. These findings are similar to our observations describing a B-ALL dependency on Runx expression and to published findings showing RUNX inactivation in myeloid or T-cell malignancies. Such contrasting roles for an established cancer pathway have been documented for deregulated Notch signaling (Klinakis et al. 2011 ). However, unlike aberrant Notch activity, the effects of Phf6 and Runx suppression were observed only in vivo, suggesting that the tumor microenvironment can strongly influence these ''lineage-specific'' genetic dependencies.
To gain insight into the molecular function of PHF6 in leukemia, we performed whole-genome chromatin immunoprecipitation (ChIP) coupled with high-throughput sequencing (ChIP-seq) using an antibody directed against Phf6 (Supplemental Fig. 8A,B) . Using Jurkat cells, a system in which chromatin regulators and histone modifications have been extensively characterized, we found that Phf6 was bound to the promoter regions and within the gene body of many annotated genes (Supplemental Fig. 8C ). Phf6 most frequently occupied the promoter region of active genes, as evidenced by co-occupancy with RNA polymerase II (RNAP2) and the histone modification H3K4me3 (Fig. 4A,B) . Interestingly, when we ranked the genes bound by Phf6 based on ChIP-seq signal ( Fig. 4C-F ; Supplemental Table 6 ), we identified a set of target genes that have established roles in hematopoietic malignancies. This gene set included RUNX1, DMNT3A, NOTCH1, and JAG1 (a ligand of Notch). These data suggest that PHF6 may be involved in a gene regulatory network that influences disease progression through the modulation of other leukemiaassociated genes. Consistent with this idea, Phf6 suppression resulted in a significant decrease in Runx1 and Notch levels in B-ALL cells (Supplemental Fig. 9A-C) .
The tractable characteristics of this murine pre-B-cell leukemia permit the introduction of very large, diverse libraries of shRNAs into individual animals. Specifically, malignant cells in this model show very high engraftment efficiency into syngeneic recipient mice. This efficiency allows for the simultaneous assessment of the impact of thousands of loss-of-function events in individual tumors. However, the ultimate relevance of this approach lies in the number of genes and gene classes that specifically impact leukemia cell growth in vivo. Here, we identified a large set of ''context-specific'' dependencies or acquired genetic dependency genes that become important for tumor progression only following transplantation into the tumor's native microenvironment. These data also highlight the relevance of tumor type to cancer therapy. While many current therapeutic strategies focus on targeting cancer-specific alterations, our data suggest that the effects of targeting the same cancer-relevant pathways may yield dramatically distinct-and possibly oppositeoutcomes depending on tumor cell identity.
Materials and methods

Cell culture
Bcr-Abl-driven mouse acute B-cell lymphoblastic leukemia cells (Williams et al. 2006) were cultured in RPMI supplemented with 10% FBS, 4 mM L-glutamine, and 5 mM b-mercaptoethanol. T-cell lymphomas were derived from p53-deficent animals and maintained in IMDM with 10% FBS and 5 mM b-mercaptoethanol. MLL-AF9-expressing AML cells were maintained in RPMI with 10% FBS, 4 mM L-glutamine, and 500 mM b-mercaptoethanol.
RNAi screening and validation assays
The shRNAs were expressed in a mir30 context, and the precise vector construction has been detailed in the referenced mir30 shRNA study (Dickins et al. 2005) . Detailed screening and validation library information is provided in the Supplemental Material. PCR primer sequences are provided in Supplemental Table 7 . Quantitative PCR (qPCR) reactions were performed on cDNA using the primer sequences in Supplemental  Table 8 . Knockdown data not shown in the figures are shown in Supplemental Table 9 .
Microarray analysis
GFP-expressing leukemia cells (1 3 10 6 ) were injected into nonirradiated C57BL/6J syngeneic recipient animals or propagated in culture. After 12 d of growth in each condition, 2 3 10 6 leukemia cells were sorted from the peripheral blood of tumor-bearing animals or from cultured samples and flash-frozen. RNA was extracted from leukemia cells with an RNeasy kit (Qiagen), and microarrays were performed by the Massachusetts Institute of Technology BioMicro Center using Affymetrix Mouse Genome 430 2.0 arrays.
Western blotting
For Western blots, ALL cells were infected with individual shRNAs coexpressing GFP to a final infection percentage of 40%-60% and sorted based on GFP expression, and total protein was isolated from this sorted cell population. Proteins were detected with the following antibodies: Phf6 (1:1000 in TBS-T with 5% BSA; Novus Biologicals, NB100-68262), Runx1 (1:1000 in TBS-T with 5% BSA; Abcam, ab23980), and HSP60 (1:1000 in TBS-T with 5% BSA; Santa Cruz Biotechnology, SC1722). ImageJ was used to perform protein densitometry.
ChIP-seq
The antibody used for ChIP-seq was specific for PHF6 (Bethyl Laboratories, A301-451A). All protocols for Illumina sample preparation, sequencing, and quality control were provided by Illumina (http://www.illumina.com). Each gene in the human genome was classified into active, initiated, bivalent, or PcG-bound or silent groups based on the presence of co-occupancy of H3K4me3, H3K79me2, and H3K27me3. Using a hypergeometric test, the P-value for enrichment of PHF6 binding to the genes in each of these classes was determined. 
